SinoMab BioScience Limited announced the successful dosing of the first cohort of healthy subjects with the subcutaneous formulation of SM17 in a bridging study in China. As of the announcement date, all participants tolerated the treatment well, and no adverse events, including injection site reactions, were reported. The study aims to assess the safety, tolerability, and pharmacokinetic profiles of SM17 administered subcutaneously. Preclinical and Phase 1 data on SM17's safety and pharmacokinetics have been previously published in peer-reviewed journals. The results of this bridging study have not yet been presented.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SinoMab BioScience Ltd. published the original content used to generate this news brief on October 14, 2025, and is solely responsible for the information contained therein.